TWELVE DAYS BEAUTY

Brand Owner Address Description
12 DAYS OF BEAUTY THE RYZMAN FAMILY PARTNERSHIP 2220 Gaspar Avenue, Los Angeles CA 90040 TWELVE DAYS OF BEAUTY; ONE TWO DAYS OF BEAUTY;Cosmetic preparations for the eye, artificial eyelashes, artificial individual eyelashes, adhesives for affixing artificial eyelashes, adhesives for affixing individual artificial eyelashes, eyelash adhesive remover; non-medicated skin care preparations, namely; bath soaps; facial creams; moisturizers for the face, hands and body; beauty masks; skin cleansers and toners; anti-aging creams; non-medicated serums for use on the skin; cosmetic tanning preparations; preparations for the hair, namely, shampoo, conditioner, pomades; hair sprays; shaving and aftershave preparations; cosmetic products, namely, lipsticks, lip gloss, lip liners, lip balms, eye shadows, eye lining pencils, liquid eye liners, eye makeup, mascara, eyebrow pencils, blushes, bronzers, multi-use cosmetic sticks, foundation makeup, pressed powders, loose powders, makeup removers, concealers, eye palettes, lip palettes, multi-use colored creams, powders and gels for use on face; nail polish, nail enamel, nail polish remover; make-up kits comprised of artificial eyelashes, adhesive for affixing artificial eyelashes, eyeliner, mascara, eye shadow, liquid eyeliner, eyeliner pencil, eyeliner marker, eyebrow pencil, eyebrow marker, lip gloss, lip liner, lip balm, lip stain, liquid lipstick, eyebrow gel, concealer;BEAUTY;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention is directed to a method to prevent or reduce postoperative corneal subepithelial haze after excimer laser photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK) surgery. According to the method, a therapeutically effective amount of one or more plasminogen activators, most preferably urokinase (uPA), is administered topically to the surface of the affected eye at levels between 0.1 and 2,500 IU/ml, about eight to twelve times on the day of surgery, and four to eight times per day for about the next six to twelve days thereafter. The most preferred therapeutic amount is from about 0.1-1 IU uPA/ml, and also 1-10 IU/ml. Plasminogen activators that can be used in the inventions include urokinase, prourokinase, streptokinase and mutants thereof. The invention also covers topical ophthalmic compositions that include one or more plasminogen activators, most preferably uPA, to prevent or reduce postoperative corneal subepithelial haze.